Showing results (131-140 of 142) with videos related to

Sort By:
Pageof 15
Cancer Chemotherapy and Pharmacology|May 24, 2021
Phase II study of trifluridine/tipiracil (TAS-102) therapy in elderly patients with colorectal cancer (T-CORE1401): geriatric assessment tools and plasma drug concentrations as possible predictive biomarkersMasanobu Takahashi, Yasuhiro Sakamoto, Hisatsugu Ohori, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 29, 2023
Phase III study of bilayer sustained-release tramadol tablets in patients with cancer pain: a double-blind parallel-group, non-inferiority study with immediate-release tramadol capsules as an active comparatorMasaharu Shinkai, Noriyuki Katsumata, Shinichi Kawai, et al.
Clinical Colorectal Cancer|September 3, 2018
Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical TrialsTakayuki Yoshino, Kentaro Yamazaki, Eiji Shinozaki, et al.
BMJ Open|May 9, 2022
Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancerShintaro Nakano, Yasuyuki Kawamoto, Satoshi Yuki, et al.
Targeted Oncology|March 1, 2024
A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018GToshihiko Matsumoto, Yoshiyuki Yamamoto, Masahito Kotaka, et al.
Future Oncology (London, England)|February 17, 2015
Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPPYoshimitsu Kobayashi, Yoshito Komatsu, Satoshi Yuki, et al.
Targeted Oncology|January 9, 2024
Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal CancerYu Sunakawa, Yasutoshi Kuboki, Jun Watanabe, et al.
Annals of Surgical Oncology|November 11, 2023
Phase II Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 and Cisplatin for Gastric Cancer with Peritoneal MetastasisDaisuke Kobayashi, Yasuhiro Kodera, Ryoji Fukushima, et al.
Frontiers in Oncology|November 28, 2022
Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodiesHiroshi Nakatsumi, Yoshito Komatsu, Tetsuhito Muranaka, et al.
Cancer Science|July 6, 2025
ONO-4578 Plus Nivolumab in Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction CancerAkihito Kawazoe, Kensei Yamaguchi, Tetsuya Hamaguchi, et al.
Pageof 15